Literature DB >> 7926260

Mechanism of antiandrogen action: conformational changes of the receptor.

C W Kuil1, E Mulder.   

Abstract

Androgen receptor mRNA was translated in vitro, and androgen- and antiandrogen-bound receptor complexes were studied using limited proteolytic digestion by trypsin. Partial proteolysis of androgen-bound receptor protein resulted in a 29-kDa proteolysis-resisting fragment, whereas antiandrogen binding stabilised a 35-kDa fragment. Both fragments contain the entire ligand binding domain, and the 35-kDa fragment extended into the hinge region of the receptor. Several antiandrogens show agonistic properties for a mutated androgen receptor (LNCaP cell variant); trypsin digestion of antiandrogen-bound mutated receptor also resulted in a 29-kDa fragment. Our results point to an important difference between antiandrogens and antagonists of other steroid hormone receptors. Antiandrogens result in protection of both the hinge region and C-terminus of the androgen receptor agonist proteolytic attack, whereas other studies showed that antiestrogens and antiprogestagens expose the C-terminal end of the ligand binding domain of their respective receptors to protease. Differences in conformation of the hinge region distinguish androgen-bound from antiandrogen-bound receptor complexes, which represents an important feature of antiandrogen action.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7926260     DOI: 10.1016/0303-7207(94)90112-0

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  7 in total

1.  Monoclonal anti-androgen receptor antibodies: production, characterization and potential diagnostic applications.

Authors:  C C Shih; W J Young; C H Wang; L P Jin; X D Ji; Q Guan; M Wang; C Chang
Journal:  Mol Cell Biochem       Date:  1999-11       Impact factor: 3.396

Review 2.  Bicalutamide in advanced prostate cancer. A review.

Authors:  K L Goa; C M Spencer
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

3.  Kinetic and thermodynamic characterization of dihydrotestosterone-induced conformational perturbations in androgen receptor ligand-binding domain.

Authors:  Ravi Jasuja; Jagadish Ulloor; Christopher M Yengo; Karen Choong; Andrei Y Istomin; Dennis R Livesay; Donald J Jacobs; Ronald S Swerdloff; Jaroslava Miksovská; Randy W Larsen; Shalender Bhasin
Journal:  Mol Endocrinol       Date:  2009-05-14

4.  Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.

Authors:  H Miyamoto; S Yeh; G Wilding; C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

5.  Cytoplasmic localization and the choice of ligand determine aggregate formation by androgen receptor with amplified polyglutamine stretch.

Authors:  M Becker; E Martin; J Schneikert; H F Krug; A C Cato
Journal:  J Cell Biol       Date:  2000-04-17       Impact factor: 10.539

Review 6.  Androgen receptor: structure, role in prostate cancer and drug discovery.

Authors:  M H Eileen Tan; Jun Li; H Eric Xu; Karsten Melcher; Eu-leong Yong
Journal:  Acta Pharmacol Sin       Date:  2014-06-09       Impact factor: 6.150

7.  Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress.

Authors:  H C Whitaker; D Patel; W J Howat; A Y Warren; J D Kay; T Sangan; J C Marioni; J Mitchell; S Aldridge; H J Luxton; C Massie; A G Lynch; D E Neal
Journal:  Br J Cancer       Date:  2013-07-23       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.